Imetelstat: a first-in-class telomerase inhibitor

A unique molecule targeting a hallmark of cancer

2020 Virtual Annual Meeting of Stockholders

Event details are available

Stockholder Letter
from our CEO

Read more 

Together we can make a difference in patients’ lives

Partnering is a key to our success

A visionary history

Creating a legacy of bold innovation